Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03146078 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rate of Progression in USH2A-related Retinal Degeneration

Study acronym: RUSH2A
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Dec 2029 to Dec 15, 2029v25
  2. Study sites: 16 to 14v24
  3. Re-verified, no change to tracked fieldsv23
  4. Study description expanded, about 181 words
    • Study arms: 2 to 3
    • Secondary endpoints expanded, about 3 words
    v22
  5. Study completion date: Dec 2028 to Dec 2029v21
Show 19 earlier versionsHide 19 earlier versions
  1. Primary completion date changed from estimate of Jun 2023 to Apr 28, 2023
    • Study completion date: Jun 2023 to Dec 2028
    v20
  2. Primary and study completion dates: Apr 2023 to Jun 2023v19
  3. Primary and study completion dates: Jan 2023 to Apr 2023v18
  4. Re-verified, no change to tracked fieldsv17
  5. Primary endpoints revised (6)v16
  6. Study sites revised (16)v15
  7. 3 versions Re-verified since Feb 19, 2021, no change to tracked fieldsv12-v14
  8. Study sites revised (16)v11
  9. Re-verified, no change to tracked fieldsv10
  10. Study title shortened, about 1 wordv9
  11. Study sites revised (16)
    • Collaborators: 3 to 1
    v8
  12. Study sites: 21 to 16v7
  13. Primary completion date: May 2021 to Jan 2023
    • Study completion date: Jul 2021 to Jan 2023
    v6
  14. Enrollment target: estimated 120 to confirmed 127v5
  15. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 21 of 21 sites
    v4
  16. Study completion date: May 2021 to Jul 2021
    • Start date changed from estimate of Jun 2017 to Aug 11, 2017
    • Site details revised at 9 of 21 sites
    v3
  17. Start date: May 2017 to Jun 2017v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with USH2A related retinal degeneration associated with congenital hearing loss (Usher syndrome type 2a) or non-syndromic retinitis pigmentosa (RP39). RUSH2A Extension Study: The purpose of this addendum is to extend RUSH2A to 7- and 9-year visits, with the goal to use longer term data to further develop and support early candidate endpoints as possible clinical trial outcomes.
Trial Details
NCT Number NCT03146078
Lead Sponsor Jaeb Center for Health Research
Collaborators: Foundation Fighting Blindness
Conditions
(from sponsor)		 Usher Syndrome, Type 2A, Retinitis Pigmentosa 39
Related terms Usher syndrome, type 2A
Enrollment 127 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov